Company: APXIF
Filing Date: 2025-07-18
Form Type: F-4/A
Source: 0001213900-25-065703
Chunk: 362

Company: APx Acquisition Corp. I
Filing Date: 2025-07-18
Form: F-4/A
Chunk 362
---
 of our business operations. It is our belief that these drivers function collaboratively to reinforce and broad our role in the emerging markets we are developing, which include the following: • Data -driven approach for health management: we are committed to providing preventative health solutions and precise clinical genetic services through our operating segments, Rewell and Heritas Diagnostics. By leveraging technology and data acquisition methods, we are able to train machine learning models that integrate our genetic, microbiome, lifestyle and/or clinical data to deliver more accurate results and foster scientific development. We perform clinical studies under stringent GCP standards to maximize the good quality of our results and comply with the regulatory agencies. We continuously collect diverse omni -modaldata across our product offerings to build robust Latin American genomic data bases. This localized approach addresses the challenges faced other players in the region who rely on foreign markets for sample processing, often resulting in inaccurate outcomes due to the absence of region -specificdata. • Artificial intelligence: from the foundation AI models in genomics to the development of clinically oriented LLMs, we apply algorithms to improve the quality of our results. Through our product offering we plan on providing genomic sequencing, proprietary data processing, and comprehensive artificial intelligence analysis to further develop our current and future products. In addition to using AI for data interpretation and processing, we plan to develop AI Agents designed to interact directly with customers. We expect that AI Agents will play a role in providing personalized health guidance, interpreting results, and supporting telemedicine services, allowing us to scale our offerings. Furthermore, we value the use of technology breakthroughs and advancements in self and remote testing, as we plan on collecting complete omni -modaldata to accelerate our innovations, improve localized results and develop future products. 178 • Customer experience: we view customer experience for patients, physicians, healthcare providers, and partners as a fundamental element of our long -termgrowth strategy and a powerful tool to facilitate the integration of genetics into mainstream medicine. We believe that providing excellent products and ensuring “ease -of-use,” such as onboarding, streamlined ordering, results interpretation and fast turnaround times, are key for all our customers. As such, our products and services are developed based on user insights, local languages and cultures, operations and logistics requirements, and unmet market needs that we have identified. We have a track record that has allowed us to achieve product market fit with our services. As such, we believe OmnigenicsAI’s products can play a pivotal role in revolutionizing health management. • Adoption: we anticipate that,